ARCA股东预计将拥有合并后公司约2.38%的股份,而Oruka股东预计将拥有约97.62%的股份。
合并后的公司将以Oruka Therapeutics的名义运营,并在纳斯达克交易,股票代码为ORKA。
Oruka已获得2.75亿美元私人投资的承...查看全文
方舟生物医药(ABIO)04-11 21:55
$方舟生物医药(ABIO)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001274173-24-000067 Act: 34 Size: 13 KB 网页链接查看全文
方舟生物医药(ABIO)04-16 05:35
$方舟生物医药(ABIO)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001013594-24-000372 Act: 34 Size: 144 KB 网页链接查看全文
方舟生物医药(ABIO)04-06 04:15
$方舟生物医药(ABIO)$ SC 13D General statement of acquisition of beneficial ownership Accession Number: 0000902664-24-002769 Act: 34 Size: 86 KB 网页链接查看全文
方舟生物医药(ABIO)04-05 04:35
$方舟生物医药(ABIO)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0000950170-24-041846 Act: 34 Size: 429 KB 网页链接查看全文
方舟生物医药(ABIO)04-10 09:05
$方舟生物医药(ABIO)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0000919574-24-002436 Act: 34 Size: 167 KB 网页链接查看全文
方舟生物医药(ABIO)04-06 07:45
$方舟生物医药(ABIO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001193125-24-088757 Act: 34 Size: 84 KB 网页链接查看全文
方舟生物医药(ABIO)04-03 19:35
$方舟生物医药(ABIO)$ 425 Prospectuses and communications, business combinations Accession Number: 0001193125-24-085440 Act: 34 Size: 4 MB 网页链接查看全文
方舟生物医药(ABIO)04-03 19:35
$方舟生物医药(ABIO)$ 8-K Current report, items 1.01, 3.02, 5.01, 5.02, 7.01, and 9.01 Accession Number: 0001193125-24-085437 Act: 34 Size: 5 MB 网页链接查看全文
方舟生物医药(ABIO)03-23 04:25
$方舟生物医药(ABIO)$ 8-K Current report, items 1.01 and 9.01 Accession Number: 0000950170-24-035373 Act: 34 Size: 184 KB 网页链接查看全文
产业链观察2022-04-01 20:36
药闻▶$方舟生物医药(ABIO)$ 发 布了rNAPc2治疗COVID-19住院患者的2b期ASPEN-COVID-19试验的结果。两个剂量水平都没有达到统计学意义上的主要疗效终点。
盘前跌近25%查看全文
北京时间2024年02月08日23时32分,方舟生物医药(ABIO.us)股票出现异动,股价急速拉升5.00%。截至发稿,该股报1.68美元/股,成交量1.5057万股,换手率0.10%,振幅2.19%。 最近的财报数据显示,该股实现营业... 网页链接
$方舟生物医药(ABIO)$ 8-K - Current report Filed: 2018-05-29 AccNo: 0001564590-18-014531 Size: 3 MBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$方舟生物医药(ABIO)$ CT ORDER - Confidential treatment order Filed: 2018-05-10 AccNo: 9999999997-18-005653 Size: 18 KB 网页链接
$方舟生物医药(ABIO)$ 8-K - Current report Filed: 2018-05-08 AccNo: 0001564590-18-011864 Size: 155 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$方舟生物医药(ABIO)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2018-05-08 AccNo: 0001564590-18-011830 Size: 4 MB 网页链接
$方舟生物医药(ABIO)$ 8-K - Current report Filed: 2018-04-23 AccNo: 0001564590-18-008752 Size: 358 KBItem 1.01: Entry into a Material Definitive AgreementItem 9.01: Financial Statements and Exhibits 网页链接
$方舟生物医药(ABIO)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2018-04-18 AccNo: 0001193125-18-120614 Size: 235 KB 网页链接
$方舟生物医药(ABIO)$ DEF 14A - Other definitive proxy statements Filed: 2018-04-18 AccNo: 0001193125-18-120604 Size: 521 KB 网页链接
$方舟生物医药(ABIO)$ 8-K - Current report Filed: 2018-04-16 AccNo: 0001564590-18-008254 Size: 29 KBItem 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 网页链接
$方舟生物医药(ABIO)$ 内部交易: 2018-04-02,VP, Finance,Selby Brian L. ,卖出,1114普通股, $0.50
$方舟生物医药(ABIO)$ 内部交易: 2018-04-03,COO,Keuer Thomas A ,卖出,482普通股, $0.50